Rheumatoid arthritis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: All inclusion criteria were met for inclusion: (1) The patient's age >= was 18 years old; (2) Physician confirmed rheumatoid arthritis, compliant with 2010 ACR/EULAR established diagnostic criteria for ra classification; (3) Ra disease activity (DAS 28 >= 2.6); Good compliance, cooperate with follow-up.
Exclusion criteria
Exclusion criteria: Subjects who meet one of the following conditions will not be enrolled in the trial: (1) Live vaccination within 4 weeks before screening; (2) Patients with malignant tumor or history of malignant tumor and the risk of treatment is greater than the benefit judged by the investigator; (3) In the active stage of systemic or local infection, the risk of treatment is greater than the benefit judged by the investigator; (4) Severe hepatic and renal insufficiency; (5) Severe center of gravity and cerebrovascular disease; (6) Pregnant women and breast-feeding women; (7) Any biological agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) prior to initiation of tocilizumab treatment; (8) A person with mental illness, a history of alcoholism, immunodeficiency, drug or other substance abuse; (9) Those who are allergic to the ingredients of this product; Other circumstances judged by the investigator to be unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Assess disease activity;Evaluating clinical efficacy based on higher standards;Assessing disease activity based on patient-reported outcomes;Assess quality of life;Evaluate drug safety;Assess the impact of drug use on hormone dosage; | — |
Countries
China
Contacts
Affiliated Hospital of Gansu University of Traditional Chinese Medicine